

June 15, 2015

IMPORTANT NOTICE: Recruitment of Oncologists, Health Economist, and Pharmacist for pCODR Expert Review Committee - Application Deadline extended to June 29, 2015

Hello,

In response to requests from stakeholders, the application deadline for the recruitment of Oncologists, Health Economist, and Pharmacist for the pCODR Expert Review Committee has been extended to **June 29, 2015**.

If you are looking for an opportunity to demonstrate national leadership and are seeking ways to impact the care that is delivered to Canadians with cancer, you may be interested in participating in the pan-Canadian Oncology Drug Review (pCODR). pCODR is currently recruiting for membership on the pCODR Expert Review Committee (pERC), due to some upcoming term expirations. We are seeking the following member types, with membership to begin September 2015 for a two or three year term:

- **Three (3) Oncologists**
- **One (1) Health Economist**
- **One (1) Pharmacist**

Also, pCODR continuously recruits oncologists to sit on the 11 clinical guidance panels, which are structured around specific tumour types, e.g. breast, endocrine, gastrointestinal, genitourinary, head and neck, leukemia, lymphoma and myeloma, lung, melanoma, neuro-oncology, sarcoma. We are also in need of economists, with knowledge of pharmacoeconomics, to participate on the economic guidance panels.

The [nomination package](#) provides a clear outline of the criteria and process to become a pERC member or a member of pCODR's clinical or economic guidance panels. Nominations/submissions for the pERC member positions will be accepted until 5:00 p.m. EDT, **June 29, 2015**. All other applications for clinical or economic panels will be accepted on an on-going basis.

Please note that pCODR is also recruiting a [pERC Chair \(Elect\)](#). The deadline to apply or be nominated for pERC Chair (Elect) is **June 29, 2015**.

If you have any questions, please contact nominations@pcodr.ca.

About pCODR

The pan-Canadian Oncology Drug Review (pCODR), a CADTH program, assesses cancer drugs and makes reimbursement recommendations to the provinces and territories to guide their drug funding decisions. pCODR is designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness, and patient perspectives.

Sincerely,

Mona Sabharwal
Executive Director